SCHEMBL970574

SCHEMBL970574

CC(=O)Oc1cc2oc(-c3ccccc3)cc(=O)c2c(Oc2ccccc2)c1OC(C)=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREB1 P16220 2/20 0.64
MAPT P10636 5/20 0.55
KDM4E B2RXH2 4/20 0.55
CYP3A4 P08684 4/20 0.55
ALDH1A1 P00352 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
HSD17B10 Q99714 2/20 0.55
HPGD P15428 2/20 0.55
ADORA3 P0DMS8 1/20 0.54
ABCG2 Q9UNQ0 4/20 0.53
ABCB1 P08183 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
ALOX12 P18054 1/20 0.53
MAPK1 P28482 1/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 1/20 0.52
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL970007 0.92 CREB1 (0.65) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL972738 0.92 CREB1 (0.70) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL971867 0.91 CREB1 (0.71) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL971180 0.88 CREB1 (0.66) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL972837 0.86 CREB1 (0.80) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL974333 0.84 ABCB1 (0.68) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL970573 0.84 CREB1 (0.63) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL16499864 0.83 KDM4E (0.69) CREB1MAPTKDM4ECYP3A4ALDH1A1
SCHEMBL29008532 0.82 CREB1 (0.86) CREB1MAPTKDM4ECYP3A4ALDH1A1
Chrysin Diacetate SCHEMBL15263635 0.82 KDM4E (0.78) CREB1MAPTKDM4ECYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875650-B2 Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone YALE UNIVERSITY (US) 2011-01-25 US disclosed
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring YALE UNIVERSITY (US) 2007-07-12 US disclosed
WO-2005075449-A1 COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING YALE UNIVERSITY (US) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161605-A1 Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring ABCB1, ABCB11, ABCG2 CREB1 2524/4885MAPT 4867/4885KDM4E 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.